GlassScriptPhysician profile
Pamela Maur
NPI 1427343532
$44,946.00
in general payments reported to CMS, 2019-2025
41 companies · $4,283 in 2025
The $4,283 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,765 · 2020: $284 · 2021: $1,638 · 2022: $11K · 2023: $14K · 2024: $12K · 2025: $4,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $11K · Travel and Lodging: $5,404 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,604.57 |
| Consulting Fee | $10,663.00 |
| Travel and Lodging | $5,403.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $21,857.15 | 2021-2025 | Linq II, Micra, Symplicity G3 |
| Abbott Laboratories | $14,161.67 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, 2nd Gen Centrimag Primary Console |
| Edwards Lifesciences Corporation | $2,188.29 | 2021-2025 | Mitris Resilia Mitral Valve, Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $1,010.04 | 2021-2025 | Watchman Flx, Watchman Access System, Avvigo Guidance System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $750.85 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $626.01 | 2019-2024 | Xarelto |
| Amgen INC. | $416.21 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $394.68 | 2019-2025 | |
| Heartflow, INC. | $389.12 | 2023-2025 | Ffrct |
| Actelion Pharmaceuticals US, INC. | $364.47 | 2019-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals LP | $307.92 | 2019-2024 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $271.98 | 2022-2025 | Verquvo |
| Inari Medical, INC. | $240.55 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.21 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $157.87 | 2023-2025 | Camzyos, Eliquis |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Maur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.